Patents by Inventor Lujia Zhou

Lujia Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting Synaptogyrin-3 in Tauopathy Treatment
    Publication number: 20220403021
    Abstract: The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
    Type: Application
    Filed: April 20, 2022
    Publication date: December 22, 2022
    Inventors: Patrik Verstreken, Joseph McInnes, Lujia Zhou
  • Targeting synaptogyrin-3 in tauopathy treatment
    Patent number: 11332526
    Abstract: The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: May 17, 2022
    Assignees: VIB VZW, Katholieke Univeriteit Leuven, K.U. Leuven R&D
    Inventors: Patrik Verstreken, Joseph McInnes, Lujia Zhou
  • TARGETING SYNAPTOGYRIN-3 IN TAUOPATHY TREATMENT
    Publication number: 20200216531
    Abstract: The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
    Type: Application
    Filed: July 16, 2018
    Publication date: July 9, 2020
    Inventors: Patrik Verstreken, Joseph McInnes, Lujia Zhou
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 10377834
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: August 13, 2019
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN. K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20180230232
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: January 16, 2018
    Publication date: August 16, 2018
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 9908943
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: March 6, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20160237166
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 18, 2016
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20150071940
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 12, 2015
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • BACE1 inhibitory antibodies
    Patent number: 8956614
    Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: February 17, 2015
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Bart De Strooper, Lujia Zhou, Wim Annaert
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 8568717
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: October 29, 2013
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Vrije Universiteit Brussel
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • BACE1 INHIBITORY ANTIBODIES
    Publication number: 20120237526
    Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: June 15, 2010
    Publication date: September 20, 2012
    Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Bart De Strooper, Lujia Zhou, Wim Annaert
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20110091446
    Abstract: The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 3, 2009
    Publication date: April 21, 2011
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans